Daniel J L Coleman
Overview
Explore the profile of Daniel J L Coleman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coleman D, Keane P, Chin P, Ames L, Kellaway S, Blair H, et al.
iScience
. 2024 Apr;
27(4):109576.
PMID: 38638836
AML is characterized by mutations in genes associated with growth regulation such as internal tandem duplications (ITD) in the receptor kinase FLT3. Inhibitors targeting FLT3 (FLT3i) are being used to...
2.
Kellaway S, Potluri S, Keane P, Blair H, Ames L, Worker A, et al.
Nat Commun
. 2024 Feb;
15(1):1359.
PMID: 38355578
Acute Myeloid Leukemia (AML) is caused by multiple mutations which dysregulate growth and differentiation of myeloid cells. Cells adopt different gene regulatory networks specific to individual mutations, maintaining a rapidly...
3.
Potluri S, Kellaway S, Coleman D, Keane P, Imperato M, Assi S, et al.
Leukemia
. 2024 Jan;
38(2):403-407.
PMID: 38172329
No abstract available.
4.
Coleman D, Keane P, Luque-Martin R, Chin P, Blair H, Ames L, et al.
Cell Rep
. 2023 Dec;
42(12):113568.
PMID: 38104314
Acute myeloid leukemia (AML) is a heterogeneous disease caused by different mutations. Previously, we showed that each mutational subtype develops its specific gene regulatory network (GRN) with transcription factors interacting...
5.
Coleman D, Keane P, Luque-Martin R, Chin P, Blair H, Ames L, et al.
bioRxiv
. 2023 Jul;
PMID: 37503022
AML is a heterogenous disease caused by different mutations. We have previously shown that each mutational sub-type develops its specific gene regulatory network (GRN) with transcription factors interacting with multiple...
6.
Kellaway S, Coleman D, Cockerill P, Raghavan M, Bonifer C
Exp Hematol
. 2022 Mar;
111:1-12.
PMID: 35341804
The transcription factor RUNX1 is essential for correct hematopoietic development; in its absence in the germ line, blood stem cells are not formed. RUNX1 orchestrates dramatic changes in the chromatin...
7.
Bevington S, Fiancette R, Gajdasik D, Keane P, Soley J, Willis C, et al.
Front Immunol
. 2021 Jun;
12:642807.
PMID: 34108962
T cell immunological memory is established within days of an infection, but little is known about the changes in gene regulatory networks accounting for their ability to respond more efficiently...
8.
Assi S, Imperato M, Coleman D, Pickin A, Potluri S, Ptasinska A, et al.
Nat Genet
. 2018 Nov;
51(1):151-162.
PMID: 30420649
Acute myeloid leukemia (AML) is a heterogeneous disease caused by a variety of alterations in transcription factors, epigenetic regulators and signaling molecules. To determine how different mutant regulators establish AML...
9.
Volpe G, Walton D, Grainger D, Ward C, Cauchy P, Blakemore D, et al.
Sci Rep
. 2017 Sep;
7(1):11148.
PMID: 28894287
Growth Factor Independence 1 (GFI1) is a transcriptional repressor that plays a critical role during both myeloid and lymphoid haematopoietic lineage commitment. Several studies have demonstrated the involvement of GFI1...
10.
Caliskan Salihi E, Wang J, Coleman D, Siller L
Sep Sci Technol
. 2016 Jul;
51(8):1317-1327.
PMID: 27365545
In this paper, a one-pot and easy-to-handle method at room temperature without additional chemicals for the modification of graphene oxide (GO) with surfactant is found. Removal of nickel (II) ions...